Cepheid Revenues Grow 25 Percent in Q3

Nov 03, 2016

NEW YORK (GenomeWeb) – Cepheid reported after the close of the market Thursday that its third quarter revenues increased 25 percent year over year.

The Sunnyvale, California-based molecular diagnostics firm, which signed a deal in September to be acquired by Danaher for around $4 billion, released its earnings through a quarterly report filed with the US Securities and Exchange Commission.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Breaking News

Jan

30

Featured Webinar

A Long-Read vs. Short-Read Platform Comparison: Best NGS Approaches for Microbiome Studies

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.

Feb

21

Featured Webinar

Case Study: 'Companion Informatics' to Automate Immunotherapy Manufacturing and Treatment

This webinar will provide a first-hand look at how Gradalis, a clinical-stage immunotherapy developer, is using an information management solution from L7 to streamline its research, clinical, and manufacturing operations.

Feb

26

Featured Webinar

A Cellular and Molecular Phenotyping Pipeline for Target Characterization in FFPE Biobank Samples

This webinar will demonstrate how a research team at the Firestone Institute for Respiratory Health at McMaster University developed a cellular and molecular phenotyping pipeline using archived samples of lung tissue derived from patients diagnosed with fibrotic interstitial lung disease.

Main menu